Preferred Label : angiotensin II;
MeSH definition : An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin
I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING
ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION
and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS
or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.;
MeSH synonym : angiotensin-(1-8) octapeptide; ang-(1-8)octapeptide;
CISMeF synonym : II, 5-L-Isoleucine angiotensin;
Wikipedia automatic translation : Angiotensin;
MeSH hyponym : angiotensin II, Ile(5)-; angiotensin II, Val(5)-; Angiotensin II, Valine(5)-; Valyl(5)-Angiotensin II; Angiotensin II, Isoleucine(5)-; 5-L-Isoleucine Angiotensin II; 5 L Isoleucine Angiotensin II; Angiotensin II, 5-L-Isoleucine; Isoleucine(5)-Angiotensin; Isoleucyl(5)-Angiotensin II;
MeSH CAS label : angiotensin II;
MeSH Related Number : 4474-91-3 (human);
Registry Number MeSH : 11128-99-7;
Wikipedia link : https://en.wikipedia.org/wiki/Angiotensin;
Is substance : O;
Origin ID : D000804;
UMLS CUI : C0003009;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Indexing information
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- DD 3487 [MeSH Supplementary Concept]
- See also
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin
I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING
ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION
and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS
or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
https://www.has-sante.fr/jcms/p_3491848/fr/giapreza-acetate-d-angiotensine-ii-hypotension-refractaire-dans-les-chocs-distributifs
2024
false
false
false
France
Giapreza
angiotensin II
insurance, health, reimbursement
treatment outcome
vasoconstrictor agents
shock
infusions, intravenous
shock, septic
Distributive shock
adult
Product containing only angiotensin II in parenteral dose form (medicinal product
form)
evaluation of the transparency committee
Angiotensin II Acetate
angiotensin II
hypotension
---
https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
angiotensin II
angiotensin II
vasoconstrictor agents
vasoconstrictor agents
product surveillance, postmarketing
shock
shock, septic
infusions, intravenous
pregnancy
breast feeding
angiotensin II
drug evaluation, preclinical
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/777
2010
false
false
false
Canada
journal article
clinical trials as topic
angiotensin II
losartan
---
